Acumen Pharmaceuticals, Inc. (ABOS)

USD 1.79

(-8.67%)

Market Cap (In USD)

107.54 Million

Revenue (In USD)

-

Net Income (In USD)

-52.37 Million

Avg. Volume

366.56 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.76-5.09
PE
-
EPS
-
Beta Value
0.039
ISIN
US00509G2093
CUSIP
00509G209
CIK
1576885
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Daniel J. O'Connell M.B.A.
Employee Count
-
Website
https://acumenpharm.com
Ipo Date
2021-07-01
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.